This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/business/2017/sep/01/indivior-heroin-treatment-patent-reckitt-benckiser-suboxone
The article has changed 5 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Indivior sees £1bn fall in value as it loses heroin treatment patent case | Indivior sees £1bn fall in value as it loses heroin treatment patent case |
| (35 minutes later) | |
| The drugs group Indivior has seen more than £1bn wiped off its stock market value after it lost a US patent ruling that could pave the way for the launch of rivals to its Suboxone Film heroin substitute. | The drugs group Indivior has seen more than £1bn wiped off its stock market value after it lost a US patent ruling that could pave the way for the launch of rivals to its Suboxone Film heroin substitute. |
| The company, spun out of Reckitt Benckiser in 2014, said it would appeal against the Delaware court decision that the generic drug maker Dr Reddy’s had not infringed its patents. Indivior’s shares plunged 38% to 255p after news of the ruling. | The company, spun out of Reckitt Benckiser in 2014, said it would appeal against the Delaware court decision that the generic drug maker Dr Reddy’s had not infringed its patents. Indivior’s shares plunged 38% to 255p after news of the ruling. |
| The chief executive, Shaun Thaxter, said: “Today’s news is disappointing … given the belief that the company has in its intellectual property for Suboxone Film … We remain confident in Indivior’s long-term outlook and vision.” | The chief executive, Shaun Thaxter, said: “Today’s news is disappointing … given the belief that the company has in its intellectual property for Suboxone Film … We remain confident in Indivior’s long-term outlook and vision.” |
| The company said it was not possible to quantify precisely what effect the launch of a generic competitor would have on its revenues but admitted such a move “could potentially result in a rapid and material loss of market share for Suboxone Film in the US”. | The company said it was not possible to quantify precisely what effect the launch of a generic competitor would have on its revenues but admitted such a move “could potentially result in a rapid and material loss of market share for Suboxone Film in the US”. |
| The average market share of Suboxone Film in the US was 6% in 2016, it said, and it accounted for 80% of Indivior’s total revenues last year. | The average market share of Suboxone Film in the US was 6% in 2016, it said, and it accounted for 80% of Indivior’s total revenues last year. |
| Indivior said if pharmacies could substitute Suboxone Film with a generic rival without direct consultation with the patient it could lead to the firm’s treatment losing up to 80% of its market share “within a matter of months”. | |
| Indivior said in June it had won a US patent battle against Actavis and Par Pharmaceutical over Suboxone Film. | Indivior said in June it had won a US patent battle against Actavis and Par Pharmaceutical over Suboxone Film. |
| James Vane-Tempest, an analyst at Jefferies, said: “Although today’s update is disappointing, in our view the situation is not as bad as this scenario would suggest given: 1) the appeals process can take 12-18 months; 2) Indivior has a strong balance sheet; 3) if the [rival treatment] launches in the first quarter of 2018, there is potentially a year to convert stable patients on to the new formulation, thus reducing the market opportunity of the film generic if the timings are as per our base case; and 4) the scenario doesn’t consider any change in Indivior’s business model – given Indivior’s fixed and sizeable cost base there is the potential for significant savings if needs be to weather any profitability impact.” | James Vane-Tempest, an analyst at Jefferies, said: “Although today’s update is disappointing, in our view the situation is not as bad as this scenario would suggest given: 1) the appeals process can take 12-18 months; 2) Indivior has a strong balance sheet; 3) if the [rival treatment] launches in the first quarter of 2018, there is potentially a year to convert stable patients on to the new formulation, thus reducing the market opportunity of the film generic if the timings are as per our base case; and 4) the scenario doesn’t consider any change in Indivior’s business model – given Indivior’s fixed and sizeable cost base there is the potential for significant savings if needs be to weather any profitability impact.” |
| Nick Keher at RBC Europe said there were still several possible outcomes following the ruling. He said: “The one positive from this news is that Indivior’s patents were upheld, and Dr Reddy’s was found to not be infringing on said patents. This could potentially help offset any future generic challenges, as [they] must also show to not be infringing. This could limit the number of competitors and hence the market share loss of Subuxone Film.” |